Sharpening nature's tools for efficient tuberculosis control: A review of the potential role and development of host-directed therapies and strategies for targeted respiratory delivery

Centuries since it was first described, tuberculosis (TB) remains a significant global public health issue. Despite ongoing holistic measures implemented by health authorities and a number of new oral treatments reaching the market, there is still a need for an advanced, efficient TB treatment. An a...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2016-07, Vol.102, p.33-54
Main Authors: O'Connor, Gemma, Gleeson, Laura E., Fagan-Murphy, Aidan, Cryan, Sally-Ann, O'Sullivan, Mary P., Keane, Joseph
Format: Article
Language:English
Subjects:
Adjunctive therapy
Ant-tubercular
Antitubercular Agents - therapeutic use
Combined Modality Therapy
Drug Delivery Systems
Drug Industry
Humans
Immunomodulation
Inhalation
Mycobacterium
Particle engineering
Pre-clinical testing
Targeted drug delivery
Tuberculosis - therapy
Vitamin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Centuries since it was first described, tuberculosis (TB) remains a significant global public health issue. Despite ongoing holistic measures implemented by health authorities and a number of new oral treatments reaching the market, there is still a need for an advanced, efficient TB treatment. An adjunctive, host-directed therapy designed to enhance endogenous pathways and hence compliment current regimens could be the answer. The integration of drug repurposing, including synthetic and naturally occurring compounds, with a targeted drug delivery platform is an attractive development option. In order for a new anti-tubercular treatment to be produced in a timely manner, a multidisciplinary approach should be taken from the outset including stakeholders from academia, the pharmaceutical industry, and regulatory bodies keeping the patient as the key focus. Pre-clinical considerations for the development of a targeted host-directed therapy are discussed here. [Display omitted]
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2016.04.024